Connect Biopharma Holdings (CNTB) Receivables (2023 - 2026)

Connect Biopharma Holdings has disclosed Receivables across 4 years of filings, most recently posting $3.0 million for Q2 2026.

• In Q2 2026, Receivables rose 1432.64% year-over-year to $3.0 million; the TTM figure through Jun 2026 stood at $3.0 million (up 1432.64% YoY), while the FY2025 annual figure was $161000.0, down 84.68% from the prior year.
• Receivables came in at $3.0 million for Q2 2026 at Connect Biopharma Holdings, up from $32000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.0 million in Q2 2026 to a low of $32000.0 in Q1 2026.
• Average Receivables over 4 years is $636875.0, with a median of $184000.0 recorded in 2025.
• Year-over-year, Receivables slumped 84.68% in 2025 and surged 1432.64% in 2026.
• Over 4 years, Receivables stood at $351000.0 in 2023, then soared by 199.43% to $1.1 million in 2024, then tumbled by 84.68% to $161000.0 in 2025, then surged by 1737.27% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $3.0 million in Q2 2026, $32000.0 in Q1 2026, and $161000.0 in Q4 2025.